Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Equity Average (2016 - 2025)

Arcadia Biosciences' Equity Average history spans 11 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Equity Average fell 41.47% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $4.8 million, down 41.47%, while the annual FY2025 figure was $5.2 million, 45.24% down from the prior year.
  • Equity Average reached $4.8 million in Q4 2025 per RKDA's latest filing, down from $5.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $44.2 million in Q2 2021 to a low of $4.8 million in Q4 2025.
  • Average Equity Average over 5 years is $19.9 million, with a median of $16.9 million recorded in 2023.
  • Peak YoY movement for Equity Average: soared 261.37% in 2021, then tumbled 54.06% in 2025.
  • A 5-year view of Equity Average shows it stood at $35.7 million in 2021, then crashed by 35.7% to $23.0 million in 2022, then crashed by 38.8% to $14.1 million in 2023, then plummeted by 41.74% to $8.2 million in 2024, then plummeted by 41.47% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Equity Average are $4.8 million (Q4 2025), $5.0 million (Q3 2025), and $6.7 million (Q2 2025).